{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:29:53Z","timestamp":1793831393332,"version":"4.6.1"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Glucagon-like peptide-1 (GLP-1) receptor agonists (liraglutide, semaglutide) and dual glucose-dependent insulinotropic polypeptide (GLP-1\/GIP) receptor agonists (tirzepatide) are approved for treatment of type 2 diabetes (T2D) and obesity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare the relative efficacy of tirzepatide, liraglutide, and semaglutide in reducing major adverse cardiovascular events (MACEs) in patients with obstructive sleep apnea (OSA) and T2D.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a retrospective cohort analysis in a large global federated database of patients with OSA and T2D. Two cohorts were generated, both with a treatment arm of patients prescribed tirzepatide. Liraglutide and semaglutide-treated patients provided the reference arms in cohort 1 and cohort 2, respectively. Cohorts underwent propensity-score matching at a 1:1 ratio for confounders. We examined rates of incident MACEs (composite outcome and individual components) over an 18-month follow up, and performed stratified analyses by body mass index, age, sex, and ethnicity. Finally, we assessed incident OSA in a secondary analysis of patients with T2D treated with tirzepatide compared with liraglutide and semaglutide.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After matching, each treatment arm included 7,836 patients in cohort 1 and 7,394 patients in cohort 2. Tirzepatide reduced the risk of incident MACEs compared with liraglutide (hazard ratio, 0.58; 95% confidence interval, 0.51\u20130.66) and semaglutide (0.86; 0.74\u20130.99). Tirzepatide was more efficacious in younger, male patients of White ethnicity. Moreover, tirzepatide reduced incident OSA compared with liraglutide (0.89; 0.82\u20130.97) but not semaglutide (0.94; 0.86\u20131.02).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients with OSA and T2D, tirzepatide is associated with a lower incidence of MACEs compared with liraglutide and semaglutide. More robust randomized, controlled evidence is needed for these drugs in patients who are at such high risk.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1513\/annalsats.202409-923oc","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T12:12:32Z","timestamp":1740744752000},"page":"1042-1052","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":23,"title":["Comparative Efficacy of Tirzepatide, Liraglutide, and Semaglutide in Reduction of Risk of Major Adverse Cardiovascular Events in Patients with Obstructive Sleep Apnea and Type 2 Diabetes: Real-World Evidence"],"prefix":"10.1093","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8066-9470","authenticated-orcid":false,"given":"Alex E.","family":"Henney","sequence":"first","affiliation":[{"name":"Department of Cardiovascular and Metabolic Medicine, University of Liverpool, Liverpool, United Kingdom"},{"name":"Department of Diabetes, Obesity and Endocrinology, University Hospital Aintree, Liverpool University National Health Service Foundation Trust, Liverpool, United Kingdom"},{"name":"Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart and Chest Hospital, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Riley","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular and Metabolic Medicine, University of Liverpool, Liverpool, United Kingdom"},{"name":"Department of Diabetes, Obesity and Endocrinology, University Hospital Aintree, Liverpool University National Health Service Foundation Trust, Liverpool, United Kingdom"},{"name":"Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart and Chest Hospital, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Anson","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular and Metabolic Medicine, University of Liverpool, Liverpool, United Kingdom"},{"name":"Department of Diabetes, Obesity and Endocrinology, University Hospital Aintree, Liverpool University National Health Service Foundation Trust, Liverpool, United Kingdom"},{"name":"Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart and Chest Hospital, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Heague","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular and Metabolic Medicine, University of Liverpool, Liverpool, United Kingdom"},{"name":"Department of Diabetes, Obesity and Endocrinology, University Hospital Aintree, Liverpool University National Health Service Foundation Trust, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema","family":"Hernadez","sequence":"additional","affiliation":[{"name":"TriNetX LLC, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uazman","family":"Alam","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular and Metabolic Medicine, University of Liverpool, Liverpool, United Kingdom"},{"name":"Department of Diabetes, Obesity and Endocrinology, University Hospital Aintree, Liverpool University National Health Service Foundation Trust, Liverpool, United Kingdom"},{"name":"Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart and Chest Hospital, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonya","family":"Craig","sequence":"additional","affiliation":[{"name":"Liverpool University Hospital National Health Service Foundation Trust, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Cuthbertson","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular and Metabolic Medicine, University of Liverpool, Liverpool, United Kingdom"},{"name":"Department of Diabetes, Obesity and Endocrinology, University Hospital Aintree, Liverpool University National Health Service Foundation Trust, Liverpool, United Kingdom"},{"name":"Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart and Chest Hospital, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"2026012203124283500_bib1","first-page":"113","article-title":"Obstructive sleep apnea as a risk factor for type 2 diabetes mellitus","volume":"7","author":"Rajan","year":"2015","journal-title":"Nat Sci Sleep"},{"key":"2026012203124283500_bib2","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.2337\/dc18-0675","article-title":"A population-based study of the bidirectional association between obstructive sleep apnea and type 2 diabetes in three prospective US cohorts","volume":"41","author":"Huang","year":"2018","journal-title":"Diabetes Care"},{"key":"2026012203124283500_bib3","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/s42003-024-06171-z","article-title":"Adipocyte-derived exosomes from obstructive sleep apnoea rats aggravate MASLD by TCONS_00039830\/miR-455-3p\/Smad2 axis","volume":"7","author":"Yang","year":"2024","journal-title":"Commun Biol"},{"key":"2026012203124283500_bib4","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/obr.12020","article-title":"Association of obstructive sleep apnoea with the presence and severity of non-alcoholic fatty liver disease. A systematic review and meta-analysis","volume":"14","author":"Musso","year":"2013","journal-title":"Obes Rev"},{"key":"2026012203124283500_bib5","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1161\/CIR.0000000000000988","article-title":"Obstructive sleep apnea and cardiovascular disease: a scientific statement from the American Heart Association","volume":"144","author":"Yeghiazarians","year":"2021","journal-title":"Circulation"},{"key":"2026012203124283500_bib6","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12933-018-0728-6","article-title":"Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017","volume":"17","author":"Einarson","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"2026012203124283500_bib7","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.2337\/dc19-2116","article-title":"Obstructive sleep apnea, a risk factor for cardiovascular and microvascular disease in patients with type 2 diabetes: findings from a population-based cohort study","volume":"43","author":"Adderley","year":"2020","journal-title":"Diabetes Care"},{"key":"2026012203124283500_bib8","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/S0140-6736(05)71141-7","article-title":"Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study","volume":"365","author":"Marin","year":"2005","journal-title":"Lancet"},{"key":"2026012203124283500_bib9","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ehj.2004.02.021","article-title":"Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome","volume":"25","author":"Coughlin","year":"2004","journal-title":"Eur Heart J"},{"key":"2026012203124283500_bib10","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026012203124283500_bib11","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.2337\/dc06-2593","article-title":"Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes","volume":"30","author":"Vilsb\u00f8ll","year":"2007","journal-title":"Diabetes Care"},{"key":"2026012203124283500_bib12","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"key":"2026012203124283500_bib13","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/dom.13125","article-title":"Liraglutide and cardiovascular outcomes in adults with overweight or obesity: A post hoc analysis from SCALE randomized controlled trials","volume":"20","author":"Davies","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2026012203124283500_bib14","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jama.2015.9676","article-title":"Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial","volume":"314","author":"Davies","year":"2015","journal-title":"JAMA"},{"key":"2026012203124283500_bib15","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"2026012203124283500_bib16","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2026012203124283500_bib17","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2026012203124283500_bib18","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/dom.15332","article-title":"5-Year simulation of diabetes-related complications in people treated with tirzepatide or semaglutide versus insulin glargine","volume":"26","author":"Niu","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"2026012203124283500_bib19","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41591-022-01707-4","article-title":"Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis","volume":"28","author":"Sattar","year":"2022","journal-title":"Nat Med"},{"key":"2026012203124283500_bib20","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/dom.15318","article-title":"Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT-1 post hoc analysis","volume":"26","author":"Hankosky","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"2026012203124283500_bib21","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"2026012203124283500_bib22","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/ijo.2016.52","article-title":"Effect of liraglutide 3.0\u2009mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE sleep apnea randomized clinical trial","volume":"40","author":"Blackman","year":"2016","journal-title":"Int J Obes (Lond)"},{"key":"2026012203124283500_bib23","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","article-title":"Tirzepatide for the treatment of obstructive sleep apnea and obesity","volume":"391","author":"Malhotra","year":"2024","journal-title":"N Engl J Med"},{"key":"2026012203124283500_bib24","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S2213-8587(20)30431-9","article-title":"Trends in predominant causes of death in individuals with and without diabetes in England from 2001 to 2018: an epidemiological analysis of linked primary care records","volume":"9","author":"Pearson-Stuttard","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026012203124283500_bib25","doi-asserted-by":"crossref","first-page":"ooad035","DOI":"10.1093\/jamiaopen\/ooad035","article-title":"A global federated real-world data and analytics platform for research","volume":"6","author":"Palchuk","year":"2023","journal-title":"JAMIA Open"},{"key":"2026012203124283500_bib26","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s40265-022-01746-8","article-title":"Tirzepatide: first approval","volume":"82","author":"Syed","year":"2022","journal-title":"Drugs"},{"key":"2026012203124283500_bib27","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.diabet.2014.10.005","article-title":"Liraglutide treatment in a patient with HIV, type 2 diabetes and sleep apnoea-hypopnoea syndrome","volume":"41","author":"Garc\u00eda de Lucas","year":"2015","journal-title":"Diabetes Metab"},{"key":"2026012203124283500_bib28","first-page":"86","article-title":"Effects of liraglutide on sleep-disordered breathing and diabetic microangiopathy in patients with type 2 diabetes mellitus and obstructive sleep apnea-hypopnea syndrome","volume":"12","author":"Liu","year":"2020","journal-title":"Chin J Diab Mellitus"},{"key":"2026012203124283500_bib29","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1007\/s11325-022-02768-y","article-title":"Efficacy and safety of liraglutide in patients with type 2 diabetes mellitus and severe obstructive sleep apnea","volume":"27","author":"Jiang","year":"2023","journal-title":"Sleep Breath"},{"key":"2026012203124283500_bib30","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1513\/AnnalsATS.202309-821OC","article-title":"Continuous positive airway pressure but not GLP1-mediated weight loss improves early cardiovascular disease in obstructive sleep apnea: a randomized proof-of-concept study","volume":"21","author":"O\u2019Donnell","year":"2024","journal-title":"Ann Am Thorac Soc"},{"key":"2026012203124283500_bib31","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"key":"2026012203124283500_bib32","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","article-title":"Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"335","author":"von Elm","year":"2007","journal-title":"BMJ"},{"key":"2026012203124283500_bib33","doi-asserted-by":"crossref","first-page":"e038856","DOI":"10.1136\/bmjopen-2020-038856","article-title":"Randomised, controlled multicentre trial of 26 weeks subcutaneous liraglutide (a glucagon-like peptide-1 receptor agonist), with or without continuous positive airway pressure (CPAP), in patients with type 2 diabetes mellitus (T2DM) and obstructive sleep apnoea (OSA) (ROMANCE): study protocol assessing the effects of weight loss on the apnea\u2013hypnoea index (AHI)","volume":"10","author":"Sprung","year":"2020","journal-title":"BMJ Open"},{"key":"2026012203124283500_bib34","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12933-024-02203-4","article-title":"Evidence that tirzepatide protects against diabetes-related cardiac damages","volume":"23","author":"Taktaz","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"2026012203124283500_bib35","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2026012203124283500_bib36","doi-asserted-by":"crossref","first-page":"e2710","DOI":"10.1210\/clinem\/dgaa327","article-title":"GIP as a therapeutic target in diabetes and obesity: insight from incretin co-agonists","volume":"105","author":"Holst","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2026012203124283500_bib37","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1001\/jama.2019.14231","article-title":"Association of metabolic surgery with major adverse cardiovascular outcomes in patients with type 2 diabetes and obesity","volume":"322","author":"Aminian","year":"2019","journal-title":"JAMA"},{"issue":"suppl","key":"2026012203124283500_bib38","first-page":"A4144","article-title":"Treatment of obstructive sleep apnea with glucagon like peptide-1 receptor agonist [abstract]","volume":"191","author":"Amin","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203124283500_bib39","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1513\/AnnalsATS.201510-697OC","article-title":"Plasma incretin levels and dipeptidyl peptidase-4 activity in patients with obstructive sleep apnea","volume":"13","author":"Matsumoto","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"2026012203124283500_bib40","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/jsr.12552","article-title":"The relationship between sleep and glucagon-like peptide 1 in patients with abnormal glucose tolerance","volume":"26","author":"Reutrakul","year":"2017","journal-title":"J Sleep Res"},{"key":"2026012203124283500_bib41","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1183\/23120541.00057-2020","article-title":"Mortality and morbidity in obstructive sleep apnoea-hypopnoea syndrome: results from a 30-year prospective cohort study","volume":"6","author":"Dodds","year":"2020","journal-title":"ERJ Open Res"},{"key":"2026012203124283500_bib42","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/resp.13808","article-title":"Clinical side effects of continuous positive airway pressure in patients with obstructive sleep apnoea","volume":"25","author":"Ghadiri","year":"2020","journal-title":"Respirology"}],"container-title":["Annals of the American Thoracic Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/22\/7\/1042\/66007629\/annalsats_22_7_1042.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/22\/7\/1042\/66007629\/annalsats_22_7_1042.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T08:13:30Z","timestamp":1769069610000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/annalsats\/article\/22\/7\/1042\/8381937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":42,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7,1]]},"published-print":{"date-parts":[[2025,7,1]]}},"URL":"https:\/\/doi.org\/10.1513\/annalsats.202409-923oc","relation":{},"ISSN":["2329-6933","2325-6621"],"issn-type":[{"value":"2329-6933","type":"print"},{"value":"2325-6621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"2024-09-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}